Parag Parikh Flexi Cap Fund Raises Stake in ITC, Trims Exposure to 3 Stocks in August 2025

Parag Parikh Flexi Cap Fund adjusted its portfolio in August 2025, raising stakes in 10 companies while reducing exposure to three companies, as per the reports. The overall portfolio size remained at 28 stocks, unchanged from July 2025.

Higher Allocation to ITC and HDFC Bank

The fund increased its holding in ITC by 72.48 lakh shares, taking the total to 12.94 crore shares in August from 12.21 crore in July. It also bought 5.09 crore shares of HDFC Bank during the month.

Other Stocks with Higher Stakes

Apart from ITC and HDFC Bank, the fund raised investments in Axis Bank, Dr. Reddy’s Laboratories, EID Parry India, ICICI Bank, Indian Energy Exchange, Kotak Mahindra Bank, Power Grid Corporation of India, and Zydus Lifesciences.

Reductions in Cipla, Maruti Suzuki, and IPCA Labs

On the trimming side, Cipla holdings fell to 89.91 lakh shares in August after selling 4.59 lakh shares. Maruti Suzuki holdings declined to 27.46 lakh shares from 30.21 lakh as 2.75 lakh shares were sold. In IPCA Laboratories, the fund reduced its stake by 3.48 lakh shares.

No New Additions or Full Exits

The fund did not add any fresh stocks or fully exit any holdings during August. Exposure in 15 companies remained unchanged, including Bajaj Holdings & Investment, CDSL, ICRA, HCL Technologies, Mahindra & Mahindra, Infosys, Bharti Airtel, MCX, Swaraj Engines, Maharashtra Scooters, and Zydus Wellness.

Fund Profile and Assets

Launched on May 24, 2013, the Parag Parikh Flexi Cap Fund is an open-ended scheme investing across large, mid, and small-cap stocks. Reports suggest that it is managed by a team including Rajeev Thakkar, Raunak Onkar, and others. As of August 31, 2025, assets under management stood at ₹1.15 lakh crore.

The fund disclosed cash, debt, money market, and arbitrage holdings of about 24.08% in August, giving flexibility for future deployment.

Conclusion

The portfolio changes in August 2025 show a preference for large financials and select consumer names while trimming exposure to a few pharma and auto stocks.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.